AdaptHealth's West Coast Contract Finally Pays — But the Balance Sheet Writes the Real Story
A beat that the tape refused to reward
AdaptHealth walked into its third-quarter print with a bruise. The shares are down roughly 38% over the last ninety trading days and sit 44% below the July 28 high of $11.22 — a collapse that began, almost to the week, around the August guidance reset and has since staged a modest 14% rebound. So the setup for this report was never "did they beat" — it was "did the story break or hold." It held, and then some: net revenue of $745.6 million rose 10.9%, organic growth of 12.8% topped guidance, and adjusted EBITDA of $141.9 million came in $11.2 million above the midpoint. Yet with an $856 million market cap riding on a heavily levered enterprise, the stock is being priced on the liabilities, not the P&L.
The single most valuable piece of new information is that the large capitated contracts thesis — the one that has dominated the company's narrative for over a year and topped internal keyword lists back in West Coast terms — has crossed from bleeding to contributing.
The West Coast contract finally pays
For four-plus quarters the market has heard the same refrain: the giant capitated arrangement (large-cap, IDN, multi-market, taken over from an incumbent with dozens of de novo locations and thousands of new staff) was running hotter on utilization and messier on workflows than it was priced for. This quarter that flipped. CFO Harriss Currie, roughly 45 days into the seat, delivered the line that matters: the contract “delivered a margin of approximately 10% in the quarter, up sequentially from a negative margin of 4% in the second quarter” — Harriss Currie, Chief Financial Officer · 2026-11-03. Management pegged the September exit run-rate at ~14% and reaffirmed a 20% target by Q4 2027. Two levers did the work — contract-dedicated headcount down more than 12% since June, and a sequential decline in the one-time capital spend that had inflated capital expenditures to 14.2% of revenue in Q3 from 18.1% year-to-date.
Then the part analysts have been circling for months: pricing. Suzanne Foster was careful not to overpromise in August (“I can't promise to any kind of renegotiation” — Suzanne Foster, Chief Executive Officer · 2026-08-04). Now the language hardened into something closer to a commitment: “We have been provided assurances that pricing adjustments are coming” — Suzanne Foster, Chief Executive Officer · 2026-11-03. Crucially, those pricing adjustments are not baked into guidance or the 20% target — the CEO was explicit that “The 20% margin does not include any adjustment. If there is something to come, it would be an improvement” — Suzanne Foster, Chief Executive Officer · 2026-11-03. That is the rare case of an unmodeled free option sitting on top of a de-risked base case, and it is why the base business contributing just 2.1 points of the 12.8% organic growth is less worrying than it looks — the capitated contract contributed 10.7 points.
One fire out, one just lit
The August call had two villains: the capitated contract and a surprise mid-year manufacturer price increase that management flagged would cost roughly $30 million in the second half. The second is now partially contained — a rebate structure was negotiated, yielding an $8 million benefit in the quarter, and the company is back to a normal annual negotiation cycle. That prior call's candor still echoes (“it was literally a bit of a surprise to us on June 30” — Suzanne Foster, Chief Executive Officer · 2026-08-04), and the fact that a negotiated outcome arrived within a quarter is a genuine de-risking.
Entirely new, though, is a supply-side shock the company did not create: Medline's field action on its home-care beds. AdaptHealth is one of Medline's largest bed customers and is now in the business of repairing and replacing product across multiple quarters while waiting for instructions on what can be fixed versus replaced. Management framed the exposure as small — beds are low single digits of revenue — with the cost passed back to Medline: “it's going to be just the time of going out and replacing or repairing those beds, and the cost associated passed back to Medline” — Suzanne Foster, Chief Executive Officer · 2026-11-03. The bottom end of guidance absorbs short-term effects. It is the kind of headline risk that keeps a beaten-down multiple pinned, even if it proves immaterial by next year.
The balance sheet is doing the talking
On a GAAP basis, net loss attributable to AdaptHealth was $168.2 million, resulting primarily from $184.8 million non-cash pre-tax goodwill impairment charge, which was triggered by the recent decline in our equity market capitalization.
That sentence is the whole tension in miniature: an accounting write-down caused by the stock collapse, in a quarter whose operating results beat. The real constraint is solvency optics. Net debt stands at $1.85 billion (down $48 million sequentially), leverage at 3.05x against a stated 2.5x target, and cash of just $80.7 million against an effective net cash position deep in negative territory. Interest coverage of 3.5x is the number management needs to protect.
The problem is cash. Free cash flow was a healthy $51.1 million in the quarter but a thin $2.6 million year-to-date, and the full-year guide was cut — “We are lowering our full year range to $55 million-$80 million” — Harriss Currie, Chief Financial Officer · 2026-11-03 — with the CFO attributing the reduction to pulling vendor payments forward to capture early-payment discounts rather than accumulating cash. He framed the current baseline as a reasonable run-rate into 2027, a claim the market will test. Management intends to throw the Diabetes Health proceeds at debt: the Diabetes Health business sale to Cardinal has cleared HSR and should close early 2027, finally completing the multi-year portfolio prune that leaves a narrower Sleep, Respiratory and Wellness business — and about $30 million of true stranded overhead the company must grow or cost-cut its way out of.
What quietly fell off the narrative is telling. Preferred provider agreement wins with four large health systems are the new growth vector, and the lifted moratorium opens fee-for-service billing in California via new PTANs — the long-promised halo effect finally being licensed. Meanwhile competitive-bidding anxiety, once a top keyword, has receded with the Diabetes divestiture, and PCS business wind-down is a diminishing drag. AdaptHealth's turnaround is no longer a question of whether the operating machine works — this quarter says it does. It is a question of whether a levered, impaired, sub-$1 billion-equity company can convert improving margins into baseline cash generation fast enough to convince the tape it deserves better than 44% off its high.